Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA

about

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA

Item

http://www.wikidata.org/entity/Q58696152

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Cardiac features and effects o ...... with Mucopolysaccharidosis IVA

@en

Cardiac features and effects o ...... with Mucopolysaccharidosis IVA

@nl

type

Item

label

Cardiac features and effects o ...... with Mucopolysaccharidosis IVA

@en

Cardiac features and effects o ...... with Mucopolysaccharidosis IVA

@nl

prefLabel

Cardiac features and effects o ...... with Mucopolysaccharidosis IVA

@en

Cardiac features and effects o ...... with Mucopolysaccharidosis IVA

@nl

P1476

Cardiac features and effects o ...... with Mucopolysaccharidosis IVA

@en

P2093

Chih-Kuang Chuang

http://www.w3.org/2001/XMLSchema#string

Chung-Lieh Hung

http://www.w3.org/2001/XMLSchema#string

Dau-Ming Niu

http://www.w3.org/2001/XMLSchema#string

Hsiang-Yu Lin

http://www.w3.org/2001/XMLSchema#string

Ming-Ren Chen

http://www.w3.org/2001/XMLSchema#string

Shan-Miao Lin

http://www.w3.org/2001/XMLSchema#string

Shuan-Pei Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Aortic Root Dilatation in Mucopolysaccharidosis I-VII

Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS).

A selective screening program for the early detection of mucopolysaccharidosis: Results of the FIND project - a 2-year follow-up study.

Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses.

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.

Mortality in patients with morquio syndrome a.

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

Echocardiographic abnormalities in type IV mucopolysaccharidosis.

Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome)

Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships.

P2888

s13023-018-0883-6

P304

148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13023-018-0883-6

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1106409151

http://www.w3.org/2001/XMLSchema#string

P698

30157891

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

6114849

http://www.w3.org/2001/XMLSchema#string